The technique involves genetically modifying certain immune cells, namely T cells. The lymphocytes are programmed with a receptor, known as CAR, and then re-injected into the patient’s body to recognize and destroy cancer cells.
Initial clinical tests on 40 young people with lymphoblastic leukaemia, although still in the early stages, produced encouraging results at Seattle Children’s Hospital between 2014 and 2016. A clinical study is scheduled at CHUV for early 2020. Prof George Coukos, head of the UNIL CHUV Oncology Department, emphasizes:
"If the findings are confirmed in the longer term, this immunotherapy is likely to revolutionize treatment for this type of cancer."
In addition to being a complex procedure, its cost – currently almost 500,000 Swiss francs – remains the biggest obstacle to widespread application.
Source: In Vivo special edition (2019) / Photo: © SAM-CHUV, Jeanne Martel
The CHUV Foundation aims to get the community involved in supporting its treatment, research and training missions. The philanthropic gestures received at the Foundation aim to optimise patient care and develop scientific knowledge in the field of health for the good of all. Patients, their family and friends, the community and the medical and care staff are at the heart of its activities.